Laura Pala

List of Publications by Year
in descending order

52 papers	1,887 citations	516710 16 h-index	276875 41 g-index
52 all docs	52 docs citations	52 times ranked	3523 citing authors

#	Article	IF	Citations
1	Sex-related differences in patients with coronavirus disease 2019. Journal of Cardiovascular Medicine, 2022, Publish Ahead of Print, 254-263.	1.5	3
2	Different Response to Immunotherapy According to Melanoma Histologic Subtype. Journal of Immunotherapy, 2022, 45, 119-124.	2.4	5
3	Boosting anticancer immunotherapy through androgen receptor blockade. Cancer Cell, 2022, 40, 455-457.	16.8	7
4	Sex and cancer immunotherapy: Current understanding and challenges. Cancer Cell, 2022, 40, 695-700.	16.8	15
5	Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. European Journal of Cancer, 2022, 171, 183-192.	2.8	4
6	Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. Cancer Treatment Reviews, 2021, 92, 102133.	7.7	4
7	Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature. Cancer Investigation, 2021, 39, 9-14.	1.3	12
8	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
9	Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers, 2021, 13, 1383.	3.7	120
10	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clinical Cancer Research, 2021, 27, 4311-4324.	7.0	44
11	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. Journal of Translational Medicine, 2021, 19, 270.	4.4	14
12	Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy. European Journal of Cancer, 2021, 153, 162-167.	2.8	10
13	Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM). ESMO Open, 2021, 6, 100188.	4.5	10
14	The effect of patient sex on the efficacy and safety of anticancer immunotherapy. Expert Opinion on Drug Safety, 2021, 20, 1535-1544.	2.4	10
15	Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. Breast, 2021, 59, 94-101.	2.2	11
16	Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials. ESMO Open, 2021, 6, 100251.	4.5	39
17	Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ, The, 2021, 375, e066381.	6.0	53
18	Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial. European Journal of Cancer, 2020, 125, 94-103.	2.8	8

#	Article	IF	Citations
19	Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19. Seminars in Oncology, 2020, 47, 302-304.	2.2	15
20	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. Frontiers in Oncology, 2020, 10, 1652.	2.8	10
21	Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097700.	3.2	6
22	Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma. Anti-Cancer Drugs, 2020, 31, 652-654.	1.4	3
23	EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Nonâ€“Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. JNCI Cancer Spectrum, 2020, 4, pkaa064.	2.9	4
24	Successful treatment with avapritinib in patient with mucosal metastatic melanoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094615.	3.2	8
25	Sexâ€based dimorphism in the SARSâ€CoV2 virulence. Journal of Internal Medicine, 2020, 288, 477-478.	6.0	2
26	Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy. Lancet Oncology, The, 2020, 21, e130.	10.7	5
27	Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors. Clinical and Translational Oncology, 2020, 22, 1818-1824.	2.4	7
28	Anti-PD1 antibodies in patients agedÂâ‰¥Â75 years with metastatic melanoma: A retrospective multicentre study. Journal of Geriatric Oncology, 2020, 11, 515-522.	1.0	31
29	Thymic epithelial tumors: From biology to treatment. Cancer Treatment Reviews, 2020, 86, 102014.	7.7	48
30	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer, 2020, 134, 19-28.	2.8	45
31	Safety and activity of Combined AVElumab with Axitinib in unresectable or metastatic Thymomas B3 and Thymic carcinomas: The CAVEATT study.. Journal of Clinical Oncology, 2020, 38, e21114-e21114.	1.6	6
32	Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast.. Journal of Clinical Oncology, 2020, 38, e12570-e12570.	1.6	0
33	Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment. Annals of Oncology, 2019, 30, 653-655.	1.2	16
34	Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors. Journal of Clinical Oncology, 2019, 37, 1838-1840.	1.6	2
35	Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2019, 111, 772-781.	6.3	144
36	Sex Differences in Efficacy and Toxicity of Systemic Cancer Treatments: Role of the Microbiome. Journal of Clinical Oncology, 2019, 37, 439-439.	1.6	16

#	Article	IF	Citations
37	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Research, 2019, 21, 153.	5.0	10
38	Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y.C. Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patientsâ€™ Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737â€“46. European Urology, 2019, 75, e34-e35.	1.9	5
39	Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma. Acta OncolÃ³gica, 2018, 57, 1131-1133.	1.8	7
40	Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. Lancet Oncology, The, 2018, 19, 737-746.	10.7	622
41	Sex as a predictor of response to cancer immunotherapy â€“ Authors' reply. Lancet Oncology, The, 2018, 19, e380-e381.	10.7	7
42	Different effectiveness of anticancer immunotherapy in men and women relies on sex-dimorphism of the immune system. Oncotarget, 2018, 9, 31167-31168.	1.8	16
43	Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib. Future Oncology, 2017, 13, 2629-2644.	2.4	8
44	Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. Oncotarget, 2017, 8, 79809-79815.	1.8	27
45	Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area. Oncotarget, 2017, 8, 47780-47789.	1.8	32
46	Dabrafenib in metastatic melanoma: a monocentric â€˜real lifeâ€™ experience. Ecancermedicalscience, 2016, 10, 624.	1.1	4
47	Safety of Combination Treatment with Imatinib Mesylate, Carboplatin, and Cetuximab in a Patient with Multiple Cancers: A Case Report. Tumori, 2016, 102, S1-S2.	1.1	1
48	Temporal course and predictive factors of analgesic opioid requirement for chemoradiationâ€induced oral mucositis in oropharyngeal cancer. Head and Neck, 2016, 38, E1521-7.	2.0	25
49	Prognostic significance of hematological profiles in melanoma patients. International Journal of Cancer, 2016, 139, 1618-1625.	5.1	40
50	Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. British Journal of Cancer, 2015, 112, 1904-1910.	6.4	191
51	The role of systemic therapy in the management of sinonasal cancer: A critical review. Cancer Treatment Reviews, 2015, 41, 836-843.	7.7	99
52	Is Postoperative Computed Tomography Evaluation a Prognostic Indicator in Patients with Optimally Debulked Advanced Ovarian Cancer?. Oncology, 2014, 87, 293-299.	1.9	10